Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.
Annette E
AE
Hay
Ralph M
RM
Meyer
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D042241:Early Diagnosis; D006509:Hepatitis B / Q000175:diagnosis* / Q000191:economics*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000191:economics* / Q000821:virology*; D011241:Prednisone / Q000009:adverse effects; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone